Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1047-1054

  Harbeck, N ^a   Iyer, S ^b   Turner, N ^c   Cristofanilli, M ^d   Ro, J ^e   Andre F ^f   Loi, S ^g   Verma, S ^h   Iwata, H ⁱ   Bhattacharyya, H ^b   Puyana Theall, K ^b   Bartlett, C H ^b   Loibl, S ^j  

^a UNIVERSITY OF MUNICH   (Germany)

^b PFIZER INC   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e National Cancer Center   (South Korea)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j German Breast Group (GBG Forschungs GmbH)   (Germany)

more..

Author keywords

Breast cancer; Endocrine resistance; Palbociclib; Patient reported outcomes; Quality of life

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; HORMONE RECEPTOR; PALBOCICLIB; PLACEBO; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ALOPECIA; ARM DISEASE; ARTICLE; BREAST DISEASE; BREAST METASTASIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FUNCTIONAL ASSESSMENT; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SYMPTOM; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PATIENT-REPORTED OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PIPERAZINES; PYRIDINES; QUALITY OF LIFE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84974800821     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw139     Document Type: Article

References (14)

1. Toogood PL, Harvey PJ, Repine JT et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406.
2. Finn RS, Dering J, Conklin D et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.
3. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35.
4. Turner NC, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373: 209-219.
5. Butters DJ, Ghersi D, Wilcken N. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2010; CD003368.
6. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential singleagent therapy in metastatic breast cancer. Oncologist 2002; 7(Suppl 6): 13-19.
7. Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptorpositive, HER2-negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 929-940.
8. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
9. Fayers PM, Aaronson NK, Bjordal K et al. EORTC QLQ-C30 Scoring Manual, 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer 2001.
10. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
11. Scott NW, Fayers PM, Aaronson NK et al. EORTC QLQ-C30 Reference Values. Brussels: European Organisation for Research and Treatment of Cancer 2008.
12. Cleeland CS, Mayer M, Dreyer NA et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: results from a substudy of the VIRGO observational cohort study. Breast 2014; 23: 763-769.
13. Warren M. Uncertainty, lack of control and emotional functioning in women with metastatic breast cancer: a review and secondary analysis of the literature using the critical appraisal technique. Eur J Cancer Care (Engl) 2010; 19: 564-574.
14. Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat 2015; 151: 679-686.